Bifidobacterium animalis as Next Generation Probiotics
The use of bacteria isolated from the gut microbiota as a source of Next Generation Probiotics (NGP) can prevent or treat chronic diseases associated with microbiota dysbiosis. With over 10 years of experience in live biotherapeutic product (LBP) development, Creative Biolabs offers a comprehensive service for your LBP project.
Introduction of Bifidobacterium animalis
Bifidobacterium animalis strains display the following characteristics typical for the genus Bifidobacterium: Gram-positive, non-motile, non-spore forming, irregular rod-shaped anaerobes. Glucose is fermented using the characteristic enzyme fructose-6-phosphate phosphoketolase in the so-called Bifidus-shunt. Dextrin, a-D-glucose, maltose, maltotriose, D-raffinose, and sucrose are fermented; the starch is not fermented. Bifidobacterium animalis and Bifidobacterium lactis were categorized as two distinct species and now are considered as Bifidobacterium animalis with two subspecies: animalis and lactis. Among different commercially available strains, Bifidobacterium animalis spp. lactis BB-12 and Bifidobacterium animalis spp. lactis DN-173010 has been studied extensively.
-
Bifidobacterium animalis subsp. lactis (B. lactis)
B. lactis is one of the most common Bifidobacterium and is commercially available as a probiotic in North America and Europe. B. lactis is a type of Gram-positive lactic acid bacterium that is commonly found in the intestines of healthy people and has been found in the intestinal flora of infants, particularly in the ileum, stool, and mucosal samples. No growth occurs on agar plates exposed to air, but 10% oxygen in the headspace atmosphere above liquid media is tolerated. Growth occurs in milk or milk-based media. Strains have been isolated from fermented milk samples, human and infant faeces, rabbit and chicken faeces and sewage. Type strain: B. lactisUR1T (LMG 18314T=DSM 10140T=JCM 10602T). Some B. lactis strains can survive in GIT, adhere to human epithelial cells in vitro, modify fecal flora, regulate host immune response, or prevent microbial gastroenteritis and colitis. Additionally, B. lactis has been reported to utilize nondigestible oligosaccharides, which may contribute to the organism’s ability to compete in the human gut. One of the probiotic strains that have been studied for its mechanism of action and clinical benefits is B. lactis 420 (B420).
-
Bifidobacterium animalis subsp. animalis (B. animalis)
Strains display characteristics typical for the species B. animalis as described above. The optimum growth temperature is 39-41℃. No growth occurs in slants incubated in the air or air enriched with carbon dioxide. Growth does not occur in milk or milk-based media. Strains originate from the faeces of rats. The DNA G+C content is 61.3 mol%. Type strain: Bifidobacterium animalis subsp. animalis R101-8T (LMG 10508T=DSM 20104T=JCM 1190T).
Bifidobacterium animalis for Disease Treatment
The research results showed that oral administration of B. animalis alone or the B. animalis/B. pseudolongum two-bacterium combination reduced the severity of the ensuing influenza infection. This might indicate that B. animalis may be developed into anti-influenza probiotics. The study also established the potential of using gut microbiota (e.g., Bifidobacterium) as a novel biomarker for predicting the severity and mortality of influenza patients, which could contribute to the development of precision medicine strategies for influenza treatment in the future.
-
Obesity and Impaired Glucose Tolerance
In the obesity model, C57Bl/6J mice were fed a high-fat diet (60 energy%) for 12 weeks, and gavaged daily with B. lactis 420 (109 CFU) or vehicle. In a diabetic model, mice were fed a high-fat, ketogenic diet for 4 weeks, followed by B. lactis 420 (108-1010 CFU/day) or control for 6 weeks, and their body composition was analyzed. The results showed that B. lactis 420 can reduce fat mass and glucose intolerance in obese and diabetic mice. The reduction of intestinal mucosal adhesion and plasma liposolysaccharide suggests a mechanism associated with reduced intestinal microbiome translocation.
Fig.1 Beneficial effects of common probiotic Bifidobacterium strains. (Chen, 2021)
What Services Can We Provide for Bifidobacterium animalisat Creative Biolabs?
Bifidobacterium animalis Related Products at Creative Biolabs
We supply a variety of Bifidobacterium animalis strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
Bifidobacterium animalis has long been used in fermented dairy products. Most Bifidobacterium animalis strains showed high gastrointestinal survival rates and confirmed probiotic properties during their survival in GIT. If your LBP project requires non-routine and unique analytical, Creative Biolabs can help save you time and money by handling all your specialty challenges. Please contact us for further discussion.
Reference
-
Chen, J.; et al. Recent development of probiotic Bifidobacteria for treating human diseases. Frontiers in bioengineering and biotechnology. 2021: 1371.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
